Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Avandia Re-Review: Three Scenarios

This article was originally published in RPM Report

Executive Summary

The Avandia advisory committee is a volatile event for GSK and the overall drug safety climate. The best and worst cases for the sponsor are not necessarily aligned with the best results for the industry overall. A look at three possible scenarios.

You may also be interested in...



Teenage Wasteland: Paying for New Drugs and Other "Adolescent" Technologies

The debate over comparative effectiveness research has focused heavily on standards of evidence to judge the relative value of different therapies and standards for when and how conclusions should drive coverage policy. Less attention has been paid to a more fundamental question: when should the value determination be made. CMS’ top coverage official has an idea that would radically change that process.

FDA Opens Up: Can Industry Live With Greater Transparency?

Drug sponsors are finding little to like about FDA's transparency initiative-especially proposals that would allow the agency to disclose more about products still in development. But given the public interest in greater transparency-and FDA's interest in avoiding another Avandia-industry needs to decide whether this is a fight worth having.

Open Minds on Avandia? A Defining Challenge for the New Regulatory Climate

The run-up to FDA's re-review of Avandia is becoming highly charged. There is a lot riding on the outcome of the agency's decision on how to deal with the diabetes therapy. Here are a number of considerations to think about going into FDA's advisory committee meeting.

Topics

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel